Pengaruh Pemberian Plasma Konvalesen terhadap Lama Rawat Inap Pasien COVID-19
DOI:
https://doi.org/10.55175/cdk.v48i7.101Keywords:
terapi plasma konvalesen, COVID-19, rawat inapAbstract
Masih meningkatnya kasus positif dan kematian COVID-19 di Indonesia menuntut fasyankes agar bisa mempersingkat durasi hospitalisasi/ rawat inap untuk efisiensi sumber daya kesehatan dan peningkatan kualitas pelayanan. Terapi adjuvan pasien rawat inap antara lain terapi plasma konvalesen (TPK). Review ini bertujuan untuk mengetahui pengaruh pemberian TPK dan terapi standar dibandingkan terapi standar saja terhadap durasi rawat inap pasien COVID-19. Penelusuran artikel secara manual pada empat database, yaitu PubMed, Cochrane, ScienceDirect, dan Scopus. Kata kunci yang digunakan adalah convalescent plasma, COVID-19 therapy, COVID-19 serotherapy, length of stay. Metode seleksi berdasarkan kriteria eligibilitas mendapatkan 1 artikel yang kemudian ditelaah kritis dari segi kesahihan, kepentingan, dan kemamputerapan. Satu artikel tinjauan sistematis merupakan artikel yang sahih dan penting, tetapi kurang memiliki kemamputerapan karena demografi dan kondisi klinis yang tidak sesuai. Review ini menyimpulkan bahwa pemberian TPK tidak memengaruhi durasi rawat inap pasien COVID-19. Diperlukan studi lebih lanjut dengan demografi dan kondisi klinis yang sesuai untuk mendapat keyakinan tertinggi.
Indonesia is still in an ongoing trend of positive cases and deaths caused by COVID-19. This condition urges health care facilities to reduce length of stay for more efficient health resources management and higher quality of care. Adjuvant therapy to hospitalized patients includes convalesent plasma therapy (CPT). This review aims to determine the effect of CPT on length of stay of COVID-19 patients in comparison to standard therapy. Literature search is through hand searching and through four databases: PubMed, Cochrane, ScienceDirect, and Scopus. Keywords used are: convalescent plasma, COVID-19 therapy, COVID-19 serotherapy, length of stay. Selection through eligibility criteria resulted in one systematic review article, then critically appraised by its’ validity, importance, and applicability.The article selected is valid and important, yet lack of applicability due to discrepancy in demographics and clinical conditions. The review concluded that CPT does not affect the length of stay of COVID-19 patients.More research with similiar demographics and clinical conditions are needed to achieve highest level of certainty.
Downloads
References
Peta sebaran COVID-19 [Internet]. 2021 Mar 08. https://covid19.go.id/peta-sebaran-covid19
Weissman GE, Crane-Droesch A, Chivers C, Luong T, Hanish A, Levy MZ, et al. Locally informed simulation to predict hospital capacity needs during the COVID-19 pandemic. Ann Intern Med. 2020 Apr 7:20-1260. doi: 10.7326/M20-1260
Mathew PJ, Jehan F, Kulvatunyou N, Khan M, O’Keeffe T, Tang A, et al. The burden of excess length of stay in trauma patients. Am J Surg. 2018;216(5):881-5. doi: 10.1016/j.amjsurg.2018.07.044. Epub 2018 Jul 31.
Hu Y, Chen Y, Zheng Y, You C, Tan J, Hu L, et al. Factors related to mental health of inpatients with COVID-19 in Wuhan, China. Brain Behav Immun. 2020;89:587–93.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, et al. Pedoman tatalaksana COVID-19. 3rd Ed. 2020 Des.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.
Chai KL, Piechotta V, Kimber C, Monsef I, Doree C, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: A living systematic review. Cochrane Database of Systematic Reviews 2020. 2020 Okt 12;CD013600(10). DOI: 10.1002/14651858.CD013600.pub3.
Gharbharan A, Jordans CEC, Geurtsvankessel C, den Hollander JG, Karim F, Mollem FPN, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. MedRxiv. 2020 Jul 3. DOI: https://doi.org/10.1101/2020.07.01.20139857
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19: A randomized clinical trial. JAMA. 2020;324(5):460-70. doi:10.1001/jama.2020.10044
Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, Thomas K, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021 Feb 11. doi: https://doi.org/10.1101/2021.02.11.21249258
Ligong L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, et al. Preventing mortality in covid-19 patients: which cytokine to target in a raging storm? Front Cell Dev Biol. 2020;8:677. Published online 2020 Jul 17. doi: 10.3389/fcell.2020.00677
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
